In spite of the current far-reaching tests to which a medicine must be subjected before authorisation, exceptionally risks may only be identified after the market launch when the product is in widespread application and everyday use. The cataloguing of spontaneous reports is still the best way to discover such problems early on.

From 1 January 2021, healthcare professionals should report adverse drug reactions directly to Swissmedic. Further information can be found here.

For the reporting of adverse vaccination reactions connected with the COVID vaccines, an adapted reporting process designed to prioritise the processing and evaluation of these reports is available via ElViS.

From 01 July 2021, only electronic reports of adverse drug reactions will be accepted from marketing authorisation holders either via a gateway connection or via the ElViS portal (Electronic Vigilance System). Further information can be found here.

All the important information about the reporting of adverse drug reactions is provided below:

Monitoring the safety of COVID-19 vaccines

To report side effects, healthcare professionals should use the online reporting tool ElViS. Doctors can log in to ElVis via HIN.